Peptide Reconstitution Calculator — Complete Vial Math for Every Stocked Compound
Three formulas cover every scenario. This is the complete walkthrough — formulas, worked examples for every peptide REVIVE LAB UAE stocks, and the unit-conversion tables that make the syringe draw obvious.
1. The three master formulas
Internalise these three. Everything else is substitution.
Concentration (mg/mL) = Vial mg ÷ Bac water mL added
Formula 2 — Volume per dose:
Volume (mL) = Desired dose (mg) ÷ Concentration (mg/mL)
Units (U-100) = Volume (mL) × 100
For micro-doses where the result is expressed in micrograms, do all calculations in μg:
Volume (mL) = Dose μg ÷ Concentration μg/mL
Units (U-100) = Volume × 100
Always keep the same mass unit on both sides of the division. Mixing mg and μg is the most common math error.
2. Worked example — Retatrutide
Vial: 5 mg. Bac water: 1 mL. Desired dose: 2 mg (Jastreboff phase 2 starting titration).
- Concentration = 5 mg ÷ 1 mL = 5 mg/mL
- Volume = 2 mg ÷ 5 mg/mL = 0.4 mL
Full Jastreboff-anchored reconstitution sits in retatrutide reconstitution math.
3. Worked example — Tesamorelin
Vial: 10 mg. Bac water: 2 mL.
- Concentration = 10 mg ÷ 2 mL = 5 mg/mL
- Volume = 2 mg ÷ 5 mg/mL = 0.4 mL
- Units = 0.4 × 100 = 40 U
4. Worked example — BPC-157 (micro-dose math)
Vial: 5 mg = 5000 μg. Bac water: 2 mL. Desired dose: 250 μg (mid-range research dose).
- Concentration = 5000 μg ÷ 2 mL = 2500 μg/mL
- Volume = 250 μg ÷ 2500 μg/mL = 0.10 mL
- Units = 0.10 × 100 = 10 U
5. Worked example — TB-500
Same micro-dose math as BPC-157. Vial: 5 mg. Standard research dose: 2 mg twice weekly (loading), then 2 mg weekly (maintenance).
6. Worked example — GHK-Cu
Vial: 50 mg or 100 mg. Topical formulations use different math (mg dissolved in g of vehicle for percentage).
7. Worked example — MOTS-c
8. Worked example — Semax (intranasal vs SC)
Vial: 10 mg. Russian clinical 0.1% formulation = 1 mg/mL.
The 10 mL reconstitution is preferred because it matches the published Russian intranasal clinical formulation concentration.
9. Worked example — NAD+ (larger doses)
Vial: 100 mg. Standard research SC dose: 50-100 mg per session.
NAD+ injections sting more than most peptides; dilute concentrations and slower push reduce site reaction. Full NAD+ context sits in NAD+ vs NMN vs NR.
10. The reverse calculation — solving for bac water volume
Sometimes you want to land a specific dose at exactly 50 U (the half-syringe sweet spot). Solve backwards:
Example: Want 250 μg of BPC-157 at exactly 50 U (0.5 mL) draw.
Bac water = 5000 μg × 0.5 mL ÷ 250 μg = 10 mL
11. Stability — how long can you keep the reconstituted vial?
| Peptide | Refrigerated stability (reconstituted) |
|---|---|
| Retatrutide | 28-30 days |
| Tesamorelin | 14 days reconstituted; freshly reconstituted weekly preferred |
| BPC-157 | 28-30 days |
| TB-500 | 28-30 days |
| GHK-Cu | 28 days (blue tint should remain; fade = degradation) |
| MOTS-c | 28-30 days |
| Semax | 28-30 days |
| NAD+ | 14-21 days |
12. UAE supply context
All peptides referenced above are stocked at REVIVE LAB UAE in HPLC-verified vials with lot-level COA. Bacteriostatic water UAE in 3 mL multi-dose vials ships in the same parcel.
Full catalogue at peptides UAE. Same-day Dubai dispatch on orders before 4 PM, 24 hours nationwide.
13. The summary
- Three master formulas cover every reconstitution problem.
- Keep units consistent (all mg or all μg) on both sides of division.
- For doses requiring >100 U, use a 3 mL syringe or split-dose at two sites.
- Reconstituted peptide vials are stable refrigerated for 14-30 days depending on compound.
References
- Manning MC, Chou DK, Murphy BM, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
- Vergote V, Burvenich C, Van de Wiele C, et al. Quality specifications for peptide drugs — a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. PubMed
- Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4(4):298-306. PubMed
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide. N Engl J Med. 2023;389(6):514-526. PubMed
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PubMed